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Abstract
Opioids are effective analgesics for pain relief, however, inappropriate use may cause risks. The aims of the study
were to evaluate trends of opioid consumption for pain management in Taiwan and compare them among neighboring
Asian countries. Opioid consumption data, including fentanyl, morphine, oxycodone, hydromorphone, codeine, and
pethidine, were collected from the Controlled Drugs Management Information System of Taiwan Food and Drug
Administration from 2008 to 2018. Data of different continents and neighboring Asian countries were retrieved from the
WHO website. The major ﬁndings include: (1) In Taiwan, the total annual opioid consumption has gradually increased
from 2008 to 2018, with fentanyl being the most frequently consumed opioid analgesic, followed by morphine. Codeine
and pethidine consumption dropped signiﬁcantly over the years. (2) In neighboring Asian countries, the opioid consumption in order from highest to lowest consumption were South Korea, Japan, Taiwan, Singapore, Hong Kong
(China), and China. We concluded that, from 2008 to 2018, the total opioid consumption trend for pain management in
Taiwan has slowly increased, with fentanyl and morphine being the most commonly used opioids. When compared with
neighboring Asian countries, level of opioid consumption in Taiwan was between Japan and Singapore. The research
results may provide a reference for healthcare professionals worldwide.
Keywords: Consumption trend, Opioid, Pain

1. Introduction

T

here are several strategies for pain management, however, in the ﬁeld of pharmacologic
management, opioids are considered the most
effective analgesics for acute, chronic, and cancer
pain management when moderate to severe pain
present [1e4]. Although opioids relieve pain, inappropriate use may cause risks, e.g., addiction, respiratory depression, and/or even death [1e4]. WHO
was also concerned about the safety use of opioid
around the world and encouraged member

countries to report opioid consumption annually
[5,6]. Since Taiwan is not a WHO member, its opioid
consumption data were not collected and analyzed
by the WHO [7]. Most opioids in Taiwan are
controlled drugs/substances and regulated by the
Taiwan Food and Drug Administration (TFDA) [7].
Based on the Taiwan Controlled Substances Act,
TFDA developed a Controlled Drug Management
Information System (CDMIS). All companies and
institutions involved in import, export, manufacture,
purchase, or sale of controlled drugs are required to
report using the CDMIS on-line reporting system
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[7]. The CDMIS collects all information of opioid
consumption in Taiwan, it is a suitable database for
research on opioid consumption. The purpose of the
study were to investigate the trends of opioid consumption for pain management in Taiwan and
make comparison among neighboring Asian
countries.

2. Material and method
Data on opioid consumption for pain from 2008 to
2018 in Taiwan were collected from the CDMIS of
TFDA. In Taiwan, all controlled drugs are classiﬁed
into four schedules based on their potential risks on
habitual use, dependency, abuse, and danger to the
public [8]. The schedule I drugs have the highest
risks and the schedule IV have the least. All opioid
analgesics are grouped into schedules I to III [8,9].
This study investigated the commonly used opioids,
including fentanyl, morphine, oxycodone, hydromorphone, codeine, and pethidine. All formulations
of these opioids were reviewed. On the basis of international comparison, data of morphine powder
for research and codeine powder for cough were
also collected. Tramadol was excluded because it is
a schedule IV drug in Taiwan and not a pure opioid
agonist but with actions on inhibition of serotonin
and norepinephrine reuptake [9,10]. Buprenorphine
and methadone were also excluded because they
are commonly used in maintenance therapy for
opioid use disorder in Taiwan [11e13]. Hydrocodone was not taken into account because it was
not available in Taiwan.
Data were presented as deﬁned daily doses for
statistical purposes per million inhabitants per day (SDDD/m/d) [5e7,14]. The number of Taiwan's inhabitants was derived from the Taiwan Ministry of
Interior population statistics database. The S-DDD
values (mg) for each opioid, obtained from the International Narcotics Control Board (INCB) 2017, were
0.6 for fentanyl, 100 for morphine, 75 for oxycodone, 20
for hydromorphone, 240 for codeine, and 400 for
pethidine [5,6,14]. The S-DDD (m/d) for each opioid of
years was derived by the following formula [5,6,14]:
annual consumption of each opioid (mg)/[S-DDD
value (mg) for each opioid  inhabitants
(million)  365 (days)].
In the WHO data [5,6], the world is divided into 6
continents. In order to investigate the opioid consumption internationally, data on 6 continents (North
America, South America, Europe, Oceania, Asia and
Africa) from 2015 to 2017 were collected [5,6]. An
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analysis of the neighboring Asian countries, including
Japan, South Korea, Singapore, China and Hong
Kong (China), was also performed [5,6]. Linear
regression analysis was used to estimate consumption
trends of each opioid in Taiwan. A p value < 0.05 was
considered signiﬁcant. In international comparison,
the absolute value of opioid consumption (S-DDD/m/
d) for each opioid or total opioids was used for the
ranking.

3. Results
3.1. Opioid consumption in Taiwan
Figure 1A shows the trends of opioid consumption
in Taiwan, including fentanyl, morphine, oxycodone, hydromorphone, codeine, and pethidine,
from 2008 to 2018. The total annual consumption of
opioids (S-DDD/m/d) was 575 in 2008 and 1107 in
2018 (an increase of 1.9 fold), among which fentanyl
was the top-ranked, followed by morphine while
other opioids only accounted for a small proportion.
The use of fentanyl, morphine, oxycodone, and
hydromorphone increased annually, and that of
codeine and pethidine presented a decreasing
trend. Figure 1B shows that the transdermal patch
was the most commonly used form of fentanyl,
followed by injection form while buccal form (ﬁlm
or tablet) accounted for only a small percentage.
Among the dosage forms, injection showed an upward trend over the years. Figure 1C shows that the
short-acting form of morphine was most commonly
used, followed by long-acting form (tablet or
capsule), injection, and oral solution. Powder that is
commonly used for research was the least
consumed form. There was a yearly upward trend in
consumption of all above dosage forms.
Figure 2A shows that the commonly used form of
oxycodone was the short-acting capsule, followed by
long-acting tablet. Both forms showed an upward
trend during this period. For hydromorphone, as
shown in Fig. 2B, only extended-release tablet was
available in Taiwan and the consumption has
increased since 2014. The most commonly used
dosage form of codeine (see Fig. 2C) was tablet, while
injection and powder forms were seldom used. There
was a signiﬁcant decline in consumption of tablet and
powder forms and the injection form showed an upward trend. Figure 2D indicates that the most
commonly used form of pethidine was injection and
tablet was rarely used. Total pethidine consumption
dropped from 25.72 in 2008 to 9.42 (S-DDD/m/d) in
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2018, showing a remarkable decline (63%) over the
years.
3.2. International comparison of opioid
consumption
Dividing the world into 6 continents, North
America had the highest opioid consumption, with
Oceania, Europe, South America, Asia and Africa
following behind (Table 1). In North America, fentanyl and oxycodone were the two most consumed
opioids followed by morphine, hydromorphone,
codeine, and pethidine. In the 6 continents, fentanyl
and oxycodone were still the two opioids most
consumed, while pethidine was the least consumed.
The data comparison among neighboring Asian
countries was made and found that South Korea
had the highest opioid consumption, followed in
order by Japan, Taiwan, Singapore, Hong Kong
(China) and China (Table 2) with fentanyl being the
most consumed, followed in order by oxycodone,
morphine, hydromorphone, codeine and pethidine.

4. Discussion

Fig. 1. The trend of opioid consumption in S-DDD per million inhabitants per day (S-DDD/m/d) from 2008 to 2018. (A) Total opioid
consumption. Trend test: total, p ¼ 0.006; fentanyl, p ¼ 0.021;
morphine, p < 0.001; oxycodone, p ¼ 0.013; hydromorphone, p ¼ 0.032;
codeine, p < 0.001; pethidine, p < 0.001. (B) Fentanyl consumption.
Trend test: total, p ¼ 0.021; transdermal, p ¼ 0.151; injection,
p ¼ 0.007; buccal, p ¼ 0.638. (C) Morphine consumption. Trend test:
total, p < 0.001; short-acting, p < 0.001; long-acting, p ¼ 0.004; injection, p < 0.001; oral solution, p ¼ 0.001; powder, p ¼ 0.001.

The major ﬁndings of the study are: (1) The total
annual consumption of opioids in Taiwan increased
gradually from 2008 to 2018 (1.9 fold), with fentanyl
being the most consumed opioid, followed by
morphine. (2) Among fentanyl dosage forms, the
transdermal patch was the most used, followed by
the injection. (3) For morphine, the short-acting
form was the most used, followed by long acting
form. (4) Pethidine consumption has declined
sharply over the years, with injection being the main
form. (5)Among the 6 continents, North America
had the highest opioid consumption, with Oceania,
Europe, South America, Asia, and Africa following
behind. (6) A comparison among neighboring Asian
countries showed that South Korea had the highest
opioid consumption, followed in order by Japan,
Taiwan, Singapore, Hong Kong (China) and China.
When dividing the world into 6 continents (Table
1), North America had the highest opioid consumption. In general, Asia countries consumed less
opioid than in other continents except Africa. According to the WHO's 2020 report [5,6], in the past 10
years, there has been a marked increase in opioid
consumption in North America and some European
countries. In United States, the opioid epidemic has
broken out, especially from 2015 to 2017 (also known
as opioid crisis) [15e17]. The safety of opioid use
thus became a primary concern [13e15]. Our study
shows that the total opioid consumption in Taiwan
has increased gradually in small amplitude in the
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Fig. 2. The trend of opioid consumption in S-DDD per million inhabitants per day (S-DDD/m/d) from 2008 to 2018. (A) Oxycodone consumption.
Trend test: total, p ¼ 0.013; long-acting, p ¼ 0.009; short-acting, p ¼ 0.024. (B) Hydromorphone consumption. Trend test: long-acting, p ¼ 0.032. (C)
Codeine consumption. Trend test: total, p < 0.001; tablet, p < 0.001; injection, p < 0.001; powder, p ¼ 0.002; (D) Pethidine consumption. Trend test:
total, p < 0.001; tablet, p < 0.001; injection, p < 0.001.

past decade. This phenomenon was also seen in
neighboring Asian countries, and may be due to the
differences between Eastern and Western cultures
and concerns about the safety use of opioids [18].
According to the WHO data [5,6], fentanyl was the
top one opioid consumed, followed in order by
oxycodone, morphine, hydromorphone, codeine
and pethidine. Global opioid consumption ranking
from 2015 to 2017 after population adjustment (S-

DDD/m/d) was headed by the United States, followed by Germany, Canada, Austria, Belgium and
other North American and European countries. In
the United States, hydrocodone was most
commonly used, with oxycodone and fentanyl being
the second and third in the ranking, respectively. In
Germany, fentanyl topped the list of the most
commonly consumed opioid, far exceeding other
opioids; in Canada, fentanyl, hydromorphone and

Table 1. The S-DDD per million inhabitants per day (S-DDD/m/d) of each opioid on each country.Data were extracted from the WHO website 2020
[5,6].
Continent

North America
Oceania
Europe
South America
Asia
Africa
total

S-DDD/m/d (2015e2017)
fentanyl

morphine

oxycodone

hydromorphone

codeine

pethidine

total

4978
4274
5293
294
102
33
14974

1337
672
384
101
19
27
2540

4846
2848
690
21
28
8
8441

1020
340
258
7
2
3
1630

57
98
13
31
5
1
205

17
14
10
8
4
8
61

12255
8246
6648
462
160
80
27851
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Table 2. The S-DDD per million inhabitants per day (S-DDD/m/d) of each opioid on neighboring Asia countries. International data were extracted
from the WHO website 2020 [5,6].
Country

S-DDD/m/d (2015e2017)
fentanyl

morphine

oxycodone

hydromorphone

codeine

pethidine

total

South Korea
Japan
Taiwan
Singapore
Hong Kong
China
total

1810
1109
580
504
76
21
4100

30
50
183
25
94
35
417

377
193
15
33
33
24
675

68
1
16
1
0
0
86

0
18
46
0
1
2
67

24
4
14
8
14
3
67

2309
1375
854
571
218
85
5412

oxycodone were the main opioids used. The mostconsumed opioids in Austria were morphine and
fentanyl; fentanyl consumption is the highest in
Belgium, far leading other opioids. Globally, the
most consumed opioid from 2015 to 2017 was fentanyl [5,6], with hydrocodone, oxycodone and
morphine following behind. In line with international trends, our study indicates that the most and
second most used opioids in Taiwan were fentanyl
and morphine. Oxycodone was introduced in
Taiwan in 2016 and therefore consumption was low
(Table 2).
Comparing neighboring Asian countries (Table 2),
South Korea had the highest opioid consumption,
followed in order by Japan, Taiwan, Singapore,
Hong Kong (China), and China. In these countries,
fentanyl was the top consumed opioid, followed in
order by oxycodone, morphine, hydromorphone,
codeine and pethidine. According to a previous
study [7] comparing opioid consumption in Taiwan
and neighboring Asian countries from 2011 to 2013,
the opioid use in Taiwan ranked between Japan and
Hong Kong (China). Our study further included
Singapore for comparison using data from 2015 to
2017, and the results showed that the ranking of
opioid consumption in Taiwan was between Japan
and Singapore.
Our study found that the total consumption of
opioid for pain in Taiwan has gradually increased.
The reason for the increase may be explained as
follows: 1. Nearly all opioid use is covered by the
National Health Insurance in Taiwan, which has
nearly 100% population coverage. Prescription opioids are easy to access and less costly [14]. 2. Since
most Schedule Class I and II opioids are manufactured by the TFDA Pharmaceutical Plant of
Controlled Drugs, with only a few being imported,
the supply is sufﬁcient to meet the demand [14]. 3.
The priority of controlled drug management in
Taiwan has been drug safety. The medical staff is
encouraged to follow the international and Taiwan's
recommendations on opioid use for pain management based on clinical presentation [19e21].

In Taiwan, fentanyl was the most consumed
opioid, in line with international trends. The transdermal patch was the most used form, followed by
the injection. Since fentanyl buccal forms (ﬁlm and
tablet) were available in Taiwan (since 2015) later
than other forms, the consumption was low.
Morphine was the second commonly use opioid;
short-acting and long-acting dosage forms were
commonly used than injection form and oral solution. The injection form is for use in hospital only
while the oral solution is used in tube feeding patients with swallowing difﬁculties. The powder form
used mostly for medical research was consumed the
least.
Our study found that codeine consumption
declined gradually during this period. The reasons
for the decline may be due to the following reasons
[14,22,23]. (1) Metabolism of codeine is genetically
determined by the highly polymorphic enzyme p450
2D6 pathway. The use of codeine in known ultrarapid metabolizers (1e2% population) or poor
metabolizers (5e10% of population) is contraindicated. (2) The use of codeine in renal failure and
dialysis is not recommended due to the accumulation of active metabolites (morphine and norcodeine). (3) Codeine is not recommended in patients
under the age of 12 due to potential serious side
effects and should be used with caution in adolescents under 18 years with obesity or pulmonary
disease. Respiratory depression and death may
occur in children with a high enzyme actions of
cytochrome p450 2D6.
We also found that pethidine consumption dropped rapidly from 25.72 in 2008 to 9.42 (S-DDD/m/d)
in 2018. Since prolonged use of pethidine may lead
to norpethidine (metabolite of pethidine) accumulation and cause central nervous system side effects,
such as seizure. There is an international consensus
to reduce pethidine consumption and replace it with
other opioids [24], and Taiwan also aligns with this
global trend. For oxycodone and hydromorphone,
the use of both drugs was low because they were
relatively new in Taiwan. However, there was a

rapidly increase in oxycodone use, especially the
short-acting form. Continuous observation of this
trend is needed.
The limitations of the study are: (1) S-DDD/m/d,
an internationally commonly method to measure
opioid consumption, was not able to study the effect
of different administration routes on the potency of
each opioid [14]. (2) Also, they did not provide information to differentiate the clinical usage (e.g.,
cancer, non-cancer, the user's age) of opioids [14].
Further studies are warranted to elucidate these
issues.

5. Conclusion
We collected and analyzed data on opioid consumption from the CDMIS of TFDA (2008e2018)
including fentanyl, morphine, oxycodone, hydromorphone, codeine, and pethidine. The results
showed that the total opioid consumption has
gradually increased in Taiwan. Fentanyl was the
most used opioid, followed by morphine while
pethidine consumption has declined rapidly over
the years. A comparison among neighboring Asian
countries showed that South Korea topped other
countries in opioid consumption, followed in order
by Japan, Taiwan, Singapore, Hong Kong (China),
and China. Since Taiwan is not a member of the
World Health Organization, the information on
opioid consumption in Taiwan is limited. Additionally, the information on trends of opioid consumption for pain management by countries is also
limited. The results of this study may serve as a
reference to both Taiwanese and international
scholars on the study of opioid consumption for
pain.
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